Nucala
Payments companies reported to CMS as associated with Nucala. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Nucala, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Nucala
These are the largest totals companies reported as associated with Nucala. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Seth Oringher | Chevy Chase, MD | $330,535.82 | |
| Bob Geng | San Diego, CA | Allergy & Immunology | $309,874.60 |
| Nabeel Farooqui | Fishers, IN | Allergy & Immunology | $275,761.28 |
| Maeve Oconnor | Charlotte, NC | Allergy & Immunology | $268,617.38 |
| Heena Shah Patel | Upland, CA | Allergy & Immunology | $268,173.63 |
| Cedric Franklin Rutland | Riverside, CA | Critical Care Medicine (Internal Medicine) | $264,506.63 |
| Christopher Melroy | Savannah, GA | Otolaryngology | $238,895.08 |
| Philip Chen | San Antonio, TX | Otolaryngology | $221,144.45 |
| Stella Cohen | Tarzana, CA | Pulmonary Disease | $207,284.69 |
| Steven Stryk | Canton, MI | Allergy & Immunology (Internal Medicine) | $197,291.19 |
Prescribed Nucala?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.